Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma
Figure 3. (A) Comparison of bile KIAA1199 levels in CCA patients (n=33) and healthy controls (n=15), p<0.001. (B) Comparison of serum KIAA1199 levels in CCA patients (n=41) and healthy controls (n=41), p<0.001. (C) ROC curve was used to evaluate serum KIAA1199 and ca199 diagnostic performances. (D, E) Kaplan-Meier analyses for overall survival (OS) and disease-free survival (DFS) in 41 CCA patients according to serum KIAA1199 levels. The quartile method is used to divide the data into four parts, and the dotted line in the figure is the dividing line of each part.